SCHEMBL7097679

SCHEMBL7097679

Cn1c(=O)n(Cc2ccccc2)c(=O)c2cc(C(=O)NCc3ccc(C#N)cc3)ccc21

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.60
SLC22A8 Q8TCC7 1/20 0.60
HDAC1 Q13547 3/20 0.52
HDAC8 Q9BY41 3/20 0.52
HDAC6 Q9UBN7 3/20 0.52
MAPT P10636 3/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPK1 P28482 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
PPARG P37231 1/20 0.48
TP53 P04637 1/20 0.48
RORC P51449 1/20 0.48
PARG Q86W56 2/20 0.47
HDAC11 Q96DB2 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6517292 0.91 MAPT (0.59) MMP13SLC22A8HDAC1HDAC8HDAC6
SCHEMBL6258857 0.90 MMP13 (0.51) MMP13SLC22A8HDAC1HDAC8HDAC6
SCHEMBL7095851 0.89 MMP13 (0.65) MMP13SLC22A8HDAC1HDAC8HDAC6
SCHEMBL7100567 0.89 MMP13 (0.56) MMP13SLC22A8HDAC1HDAC8HDAC6
SCHEMBL6532934 0.87 PPARG (0.56) MMP13SLC22A8HDAC1MAPTKDM4E
SCHEMBL7101956 0.86 MMP13 (0.54) MMP13SLC22A8HDAC1HDAC8HDAC6
SCHEMBL6246256 0.86 MAPT (0.58) MMP13SLC22A8HDAC1HDAC8HDAC6
SCHEMBL7102983 0.85 MMP13 (0.54) MMP13SLC22A8HDAC1MAPTKDM4E
SCHEMBL7102887 0.85 MMP13 (0.54) MMP13SLC22A8HDAC1MAPTKDM4E
SCHEMBL7099735 0.85 RXFP1 (0.51) MMP13SLC22A8MAPTSMN1; SMN2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP claimed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US claimed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO claimed
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MMP13 1/4885SLC22A8 315/4885HDAC1 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.